Incidence and mortality of interstitial lung disease in rheumatoid arthritis - A population-based study

Tim Bongartz, Carlotta Nannini, Yimy F. Medina-Velasquez, Sara J. Achenbach, Cynthia Crowson, Jay H Ryu, Robert Vassallo, Sherine E. Gabriel, Eric Lawrence Matteson

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Objective. Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD. Methods. We examined a population-based incidence cohort of patients with RA and a matched cohort of individuals without RA. All subjects were followed up longitudinally. The lifetime risk of ILD was estimated. Cox proportional hazards models were used to compare the incidence of ILD between cohorts, to investigate predictors, and to explore the impact of ILD on survival. Results. Patients with RA (n = 582) and subjects without RA (n = 603) were followed up for a mean of 16.4 and 19.3 years, respectively. The lifetime risk of developing ILD was 7.7% for RA patients and 0.9% for non-RA subjects. This difference translated into a hazard ratio (HR) of 8.96 (95% confidence interval [95% CI] 4.02-19.94). The risk of developing ILD was higher in RA patients who were older at the time of disease onset, in male patients, and in individuals with more severe RA. The risk of death for RA patients with ILD was 3 times higher than in RA patients without ILD (HR 2.86 [95% CI 1.98-4.12]). Median survival after ILD diagnosis was only 2.6 years. ILD contributed ∼13% to the excess mortality of RA patients when compared with the general population. Conclusion. Our results emphasize the increased risk of ILD in patients with RA. The devastating impact of ILD on survival provides evidence that development of better strategies for the treatment of ILD could significantly lower the excess mortality among individuals with RA.

Original languageEnglish (US)
Pages (from-to)1583-1591
Number of pages9
JournalArthritis and Rheumatism
Volume62
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Interstitial Lung Diseases
Rheumatoid Arthritis
Mortality
Incidence
Population
Survival
Confidence Intervals
Proportional Hazards Models
Arthritis
Comorbidity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Incidence and mortality of interstitial lung disease in rheumatoid arthritis - A population-based study. / Bongartz, Tim; Nannini, Carlotta; Medina-Velasquez, Yimy F.; Achenbach, Sara J.; Crowson, Cynthia; Ryu, Jay H; Vassallo, Robert; Gabriel, Sherine E.; Matteson, Eric Lawrence.

In: Arthritis and Rheumatism, Vol. 62, No. 6, 06.2010, p. 1583-1591.

Research output: Contribution to journalArticle

Bongartz, Tim ; Nannini, Carlotta ; Medina-Velasquez, Yimy F. ; Achenbach, Sara J. ; Crowson, Cynthia ; Ryu, Jay H ; Vassallo, Robert ; Gabriel, Sherine E. ; Matteson, Eric Lawrence. / Incidence and mortality of interstitial lung disease in rheumatoid arthritis - A population-based study. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 6. pp. 1583-1591.
@article{797bde66f6e04fd9acdb340b9eba7e9a,
title = "Incidence and mortality of interstitial lung disease in rheumatoid arthritis - A population-based study",
abstract = "Objective. Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD. Methods. We examined a population-based incidence cohort of patients with RA and a matched cohort of individuals without RA. All subjects were followed up longitudinally. The lifetime risk of ILD was estimated. Cox proportional hazards models were used to compare the incidence of ILD between cohorts, to investigate predictors, and to explore the impact of ILD on survival. Results. Patients with RA (n = 582) and subjects without RA (n = 603) were followed up for a mean of 16.4 and 19.3 years, respectively. The lifetime risk of developing ILD was 7.7{\%} for RA patients and 0.9{\%} for non-RA subjects. This difference translated into a hazard ratio (HR) of 8.96 (95{\%} confidence interval [95{\%} CI] 4.02-19.94). The risk of developing ILD was higher in RA patients who were older at the time of disease onset, in male patients, and in individuals with more severe RA. The risk of death for RA patients with ILD was 3 times higher than in RA patients without ILD (HR 2.86 [95{\%} CI 1.98-4.12]). Median survival after ILD diagnosis was only 2.6 years. ILD contributed ∼13{\%} to the excess mortality of RA patients when compared with the general population. Conclusion. Our results emphasize the increased risk of ILD in patients with RA. The devastating impact of ILD on survival provides evidence that development of better strategies for the treatment of ILD could significantly lower the excess mortality among individuals with RA.",
author = "Tim Bongartz and Carlotta Nannini and Medina-Velasquez, {Yimy F.} and Achenbach, {Sara J.} and Cynthia Crowson and Ryu, {Jay H} and Robert Vassallo and Gabriel, {Sherine E.} and Matteson, {Eric Lawrence}",
year = "2010",
month = "6",
doi = "10.1002/art.27405",
language = "English (US)",
volume = "62",
pages = "1583--1591",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Incidence and mortality of interstitial lung disease in rheumatoid arthritis - A population-based study

AU - Bongartz, Tim

AU - Nannini, Carlotta

AU - Medina-Velasquez, Yimy F.

AU - Achenbach, Sara J.

AU - Crowson, Cynthia

AU - Ryu, Jay H

AU - Vassallo, Robert

AU - Gabriel, Sherine E.

AU - Matteson, Eric Lawrence

PY - 2010/6

Y1 - 2010/6

N2 - Objective. Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD. Methods. We examined a population-based incidence cohort of patients with RA and a matched cohort of individuals without RA. All subjects were followed up longitudinally. The lifetime risk of ILD was estimated. Cox proportional hazards models were used to compare the incidence of ILD between cohorts, to investigate predictors, and to explore the impact of ILD on survival. Results. Patients with RA (n = 582) and subjects without RA (n = 603) were followed up for a mean of 16.4 and 19.3 years, respectively. The lifetime risk of developing ILD was 7.7% for RA patients and 0.9% for non-RA subjects. This difference translated into a hazard ratio (HR) of 8.96 (95% confidence interval [95% CI] 4.02-19.94). The risk of developing ILD was higher in RA patients who were older at the time of disease onset, in male patients, and in individuals with more severe RA. The risk of death for RA patients with ILD was 3 times higher than in RA patients without ILD (HR 2.86 [95% CI 1.98-4.12]). Median survival after ILD diagnosis was only 2.6 years. ILD contributed ∼13% to the excess mortality of RA patients when compared with the general population. Conclusion. Our results emphasize the increased risk of ILD in patients with RA. The devastating impact of ILD on survival provides evidence that development of better strategies for the treatment of ILD could significantly lower the excess mortality among individuals with RA.

AB - Objective. Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD. Methods. We examined a population-based incidence cohort of patients with RA and a matched cohort of individuals without RA. All subjects were followed up longitudinally. The lifetime risk of ILD was estimated. Cox proportional hazards models were used to compare the incidence of ILD between cohorts, to investigate predictors, and to explore the impact of ILD on survival. Results. Patients with RA (n = 582) and subjects without RA (n = 603) were followed up for a mean of 16.4 and 19.3 years, respectively. The lifetime risk of developing ILD was 7.7% for RA patients and 0.9% for non-RA subjects. This difference translated into a hazard ratio (HR) of 8.96 (95% confidence interval [95% CI] 4.02-19.94). The risk of developing ILD was higher in RA patients who were older at the time of disease onset, in male patients, and in individuals with more severe RA. The risk of death for RA patients with ILD was 3 times higher than in RA patients without ILD (HR 2.86 [95% CI 1.98-4.12]). Median survival after ILD diagnosis was only 2.6 years. ILD contributed ∼13% to the excess mortality of RA patients when compared with the general population. Conclusion. Our results emphasize the increased risk of ILD in patients with RA. The devastating impact of ILD on survival provides evidence that development of better strategies for the treatment of ILD could significantly lower the excess mortality among individuals with RA.

UR - http://www.scopus.com/inward/record.url?scp=77952933999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952933999&partnerID=8YFLogxK

U2 - 10.1002/art.27405

DO - 10.1002/art.27405

M3 - Article

C2 - 20155830

AN - SCOPUS:77952933999

VL - 62

SP - 1583

EP - 1591

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -